| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
Detection of IDH1 mutation in glioma through immunohistochemistry with the antibody for mutant IDH1R132H (mIDH1) is an established method. In this study, we elucidated the relation of expression between mutant IDH1 and wild type IDH1 and found diagnostic criteria for mIDH1 weakly-positive cases. In diffuse gliomas, (1) if mIDH1 is strongly positive, IDH1 mutation (G395A) is considered to be positive. (2) If mIDH1 is weakly positive, immunohistochemisty for IDH1 wild type is added. (3) If IDH1 wild type is positive, IDH1 mutation (G395A) is considered to be negative. If IDH1 wild type is weakly positive, DNA sequence is added.
|
